What's Happening?
The University of Colorado Anschutz Gates Institute has achieved a significant milestone by receiving FDA clearance for a new CAR T-cell therapy developed entirely on its campus. This therapy targets the CD64 protein on leukemia cells and is designed
for patients with relapsed or refractory acute myeloid leukemia (AML). The clearance marks the first time a CAR T-cell therapy developed on a university campus has been authorized for clinical testing in the U.S. The Phase 1 clinical trial will begin in June 2026, focusing on evaluating the safety and optimal dosing of the therapy in adults with AML. This development is the result of years of research and collaboration among scientists, clinicians, and regulatory teams at the Gates Institute.
Why It's Important?
This FDA clearance represents a major advancement in the treatment of acute myeloid leukemia, a condition with limited treatment options and poor outcomes. The development of this CAR T-cell therapy highlights the potential of university-led research to contribute to significant medical breakthroughs. By targeting a specific protein on leukemia cells, this therapy offers a novel approach that could improve survival rates for patients with this aggressive form of cancer. The success of this initiative underscores the importance of collaborative efforts in advancing cell and gene therapies, and it positions the University of Colorado Anschutz as a leader in innovative cancer treatment research.
What's Next?
The upcoming clinical trial will assess the therapy's safety and effectiveness, with patient enrollment set to begin in June 2026. The trial will be conducted at UCHealth University of Colorado Hospital, with plans to expand to pediatric trials later in the year. The Gates Biomanufacturing Facility will handle the production of the CAR T-cell product, ensuring a seamless transition from research to clinical application. As the trial progresses, the results will provide valuable insights into the therapy's potential to change the treatment landscape for myeloid leukemias, potentially leading to broader applications in other types of cancer.
